Voya Investment Management LLC Grows Position in uniQure N.V. $QURE

Voya Investment Management LLC increased its position in uniQure N.V. (NASDAQ:QURE) by 51.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 102,124 shares of the biotechnology company’s stock after buying an additional 34,864 shares during the quarter. Voya Investment Management LLC owned 0.19% of uniQure worth $5,961,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in QURE. Tower Research Capital LLC TRC boosted its holdings in shares of uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,538 shares during the period. KLP Kapitalforvaltning AS bought a new position in uniQure during the 2nd quarter valued at approximately $117,000. Teacher Retirement System of Texas purchased a new stake in uniQure in the 2nd quarter worth approximately $151,000. OMERS ADMINISTRATION Corp purchased a new stake in uniQure in the 1st quarter worth approximately $152,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of uniQure in the 2nd quarter worth approximately $215,000. 78.83% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other uniQure news, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $55.00, for a total value of $825,000.00. Following the completion of the transaction, the chief financial officer directly owned 217,730 shares of the company’s stock, valued at approximately $11,975,150. The trade was a 6.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jack Kaye sold 38,810 shares of the stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total transaction of $1,177,495.40. Following the sale, the director owned 20,439 shares in the company, valued at approximately $620,119.26. The trade was a 65.50% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 85,244 shares of company stock worth $2,859,386 in the last quarter. Corporate insiders own 4.79% of the company’s stock.

uniQure Price Performance

Shares of NASDAQ QURE opened at $25.31 on Thursday. The company has a 50 day simple moving average of $35.12 and a two-hundred day simple moving average of $26.80. uniQure N.V. has a fifty-two week low of $7.76 and a fifty-two week high of $71.50. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -5.77 and a beta of 0.59. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. Analysts expect that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Benchmark reissued a “buy” rating on shares of uniQure in a research report on Tuesday, November 4th. Mizuho cut their target price on shares of uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a research note on Monday, December 8th. HC Wainwright decreased their price target on shares of uniQure from $110.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Royal Bank Of Canada lowered their price objective on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a report on Monday, November 3rd. Finally, Chardan Capital reiterated a “buy” rating and set a $53.00 target price on shares of uniQure in a report on Thursday, December 4th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and an average price target of $60.82.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.